Abstract 252P
Background
In recent years, there has been an increase in the diagnosis of lung cancer (LC) in women, who, according to some reports, suffer from a high prevalence of sexual dysfunction (SD) associated with oncological treatments. Our aim was to describe the characteristics and risk factors for SD in a cohort of Spanish women with LC.
Methods
Analytical observational study with women included in the CLARIFY H2020 project at the Hospital Universitario Puerta de Hierro. From October 2020 to March 2023, clinical and demographic variables were collected as well as measures of sexual function using a validated Spanish-language, gender-targeted questionnaire. The frequency of sexual activity and the performance of the phases of sexual response were evaluated. Descriptive and logistic regression analyses were conducted.
Results
The overall project included 383 patients. Of these, 36.8% (141) had lung cancer and 45.4% (64) were women. 45% (30) of the men vs 36.2% (21) of the women with LC reported being sexually active. The characteristics of female population in the table. Severe dysfunction of most phases of sexual response was reported in 34-60% of women. Statistically significant associations were found in age ≥65 years OR 2.18 p0.04 (95% CI 1.01-4.7) and female gender OR 3.62 p 0.03 (95% CI 1.55-8.5) with dissatisfaction with sexual performance as well as female gender OR 3.45 p 0.004 (95% CI 1.48-8.03) and age ≥65 years OR 2.04 p 0.06 (95% CI 1.48-8.03) with severe orgasm disorder. Table: 252P
| Characteristics of women with LC included in CLARIFY project | % N 64 |
| Mean age | 63 years (range 44-85) |
| Tumoral stage | |
| Early | 53%(33) |
| Metastatic | 47%(30) |
| Marital status | |
| Married | 75%(48) |
| Separated/Divorced | 14%(9) |
| Single | 5%(3) |
| Educational level | |
| University | 38%(24) |
| Intermediate | 20%(13) |
| Basic | 2%(1) |
| No education | 40%(26) |
| Time from diagnosis | |
| ≥ 5 years | 26.6%(17) |
| 2-4 years | 60.9%(39) |
| <1 year | 12.5%(7) |
| Global sexual dissatisfaction according to treatment and tumoral stage | |
| Immunotherapy | 56%(9) |
| Chemotherapy | 68%(11) |
| Chemo immunotherapy | 50%(3) |
| Follow up | 100%(6) |
| Targeted therapy | 42%(8) |
| Early | 65%(21) |
| Metastatic | 30%(9) |
Conclusions
In our study, women with LC are at high risk of developing sexual dysfunction associated with oncologic treatment. It is necessary to screen and diagnose this disorder early and to offer multidisciplinary support to this population (Table).
Legal entity responsible for the study
The authors.
Funding
This poster is part of a project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 875160.
Disclosure
All authors have declared no conflicts of interest.